Clinical trialNCT02087423CompletedPhase 2Interventional

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

SponsorAstraZenecaEnrollment446Non-Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Phillip Dennis, MD, PhD
AstraZeneca
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

139 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria

Research Site
Vienna, Austria

Belgium

Research Site
Brussels, Belgium
Research Site
Ghent, Belgium
Research Site
Gilly, Belgium
Research Site
Kortrijk, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium

Canada

Research Site
Hamilton, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Regina, Saskatchewan, Canada

Czechia

Research Site
Brno, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia

France

Research Site
Bordeaux, France
Research Site
Brest, France
Research Site
Créteil, France
Research Site
Dijon, France
Research Site
Le Mans, France
Research Site
Marseille, France
Research Site
Pessac, France
Research Site
Rennes, France
Research Site
Saint-Herblain, France
Research Site
Toulouse, France

Germany

Research Site
Berlin, Germany
Research Site
Berlin, Germany
Research Site
Borstel, Germany
Research Site
Cologne, Germany
Research Site
Dortmund, Germany
Research Site
Frankfurt am Main, Germany
Research Site
Freiburg im Breisgau, Germany
Research Site
Großhansdorf, Germany
Research Site
Hamburg, Germany
Research Site
Heidelberg, Germany

Hungary

Research Site
Budapest, Hungary
Research Site
Budapest, Hungary
Research Site
Győr, Hungary

99 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MEDI4736

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Feb 2014
Primary completion: 3 Jun 2016
Completion: 26 Mar 2025
Last update posted: 6 Apr 2026
Registered enrollment: 446
Registry id: NCT02087423

Cross-registrations

EU-CTR / CTIS (EudraCT)2013-005427-16

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.